An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT02477826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Study identification
- NCT ID
- NCT02477826
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,747 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- Ipilimumab Drug
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
- Pemetrexed Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2015
- Primary completion
- Oct 24, 2024
- Completion
- Oct 24, 2024
- Last update posted
- Oct 29, 2025
2015 – 2024
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, Inc. | Mobile | Alabama | 36608 | — |
| Local Institution - 0017 | San Francisco | California | 94115 | — |
| Local Institution - 0021 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0001 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0013 | Marietta | Georgia | 30060 | — |
| Local Institution - 0004 | Lexington | Kentucky | 40503 | — |
| Local Institution - 0115 | St Louis | Missouri | 63110 | — |
| Local Institution - 0005 | Buffalo | New York | 14263 | — |
| Local Institution - 0019 | New York | New York | 10065 | — |
| Local Institution - 0014 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0009 | Columbus | Ohio | 43210 | — |
| Local Institution - 0007 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0075 | Langhorne | Pennsylvania | 19047 | — |
| Local Institution - 0299 | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 0012 | Philadelphia | Pennsylvania | 19111-2412 | — |
| Local Institution - 0015 | Sayre | Pennsylvania | 18840 | — |
| Local Institution - 0008 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0080 | Greenville | South Carolina | 29605 | — |
| Local Institution - 0010 | Greenville | South Carolina | 29607 | — |
| Local Institution - 0020 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0306 | Dallas | Texas | 75390-8852 | — |
| Local Institution - 0003 | Dallas | Texas | 75390 | — |
| Local Institution - 0102 | Houston | Texas | 77030 | — |
| Local Institution - 0011 | Salt Lake City | Utah | 84108 | — |
| Local Institution - 0074 | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 265 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02477826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02477826 live on ClinicalTrials.gov.